Welcome to our dedicated page for Teleflex Incorporated news (Ticker: $TFX), a resource for investors and traders seeking the latest updates and insights on Teleflex Incorporated stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Teleflex Incorporated's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Teleflex Incorporated's position in the market.
Teleflex Incorporated presented new research findings at the American Urological Association Annual Meeting showcasing superior patient experience with the UroLift™ System for BPH. The studies demonstrated better symptom relief, quality of life improvements, and patient satisfaction compared to medication and other therapies. The UroLift™ System was found to provide rapid relief and durable outcomes with preservation of sexual function.
Teleflex Incorporated (TFX) declared a quarterly cash dividend of $0.34 per share for its common stock, payable on June 14, 2024, to shareholders of record on May 15, 2024.
Teleflex Incorporated reported first quarter financial results with revenues of $737.8 million, up 3.8% YoY, and GAAP diluted EPS of $0.33. The company lowered its GAAP revenue growth guidance to 3.35%-4.35% but raised its adjusted EPS guidance. Net revenue by segment showed growth in EMEA and OEM, while net revenue by global product category saw growth in Interventional and OEM. Other financial highlights included increases in cash, accounts receivable, and inventories. The company's outlook for 2024 includes lower revenue growth on a GAAP basis but higher diluted EPS. Non-GAAP financial measures were used to assess performance, with adjustments made for restructuring, acquisition, and integration expenses.
Teleflex Incorporated (NYSE: TFX) announced multiple clinical studies at the 2024 American Urological Association Annual Meeting, showcasing the UroLift™ System to treat benign prostatic hyperplasia. The studies include head-to-head RCT data presentations, post-surgery medication use analysis, and real-world evidence studies.
Teleflex Incorporated has announced the market release of the Wattson™ Temporary Pacing Guidewire, expanding its structural heart portfolio. The device offers dual functionality, supporting valve delivery and ventricular pacing during procedures like TAVR and BAV. Designed to reduce complications, costs, and procedural steps associated with traditional pacing methods, the guidewire aims to enhance procedural efficiency and safety.
Teleflex Incorporated (NYSE: TFX) Chairman, President, and CEO Liam Kelly will present at the BofA Securities 2024 Health Care Conference on May 14, 2024, in Las Vegas. The live audio webcast will be accessible on the Teleflex website.
